Use of immunoadsorption to treat patients with severe post-COVID syndrome.
Benjamin GiszasPhilipp A ReukenKatrin KatzerMichael KiehntopfDiana SchmerlerSilke RummlerAndreas StallmachAnne KlinkPublished in: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2023)
Collectively, AAbs may play a pathophysiologic role in post-COVID and their removal provide transient benefits in some patients. However, these findings should be further investigated in randomized-controlled-trials. This article is protected by copyright. All rights reserved.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- randomized controlled trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- early onset
- systematic review
- patient reported outcomes
- clinical trial
- high resolution
- mass spectrometry
- blood brain barrier
- atomic force microscopy
- patient reported